Who is sponsoring NCT07121868?

NCT07121868 is sponsored by Aya Mohammed Abdel Magid Abdel Hamid.

What drugs are being tested in NCT07121868?

Interventions in NCT07121868: Test Product (Vocarzine), Reference (R) Reagila ®.

What condition does NCT07121868 study?

NCT07121868 studies Bioequivalence Study in Healthy Subjects.

Is NCT07121868 still recruiting?

NCT07121868 is currently completed. Last updated 17 August 2025.

Last reviewed 2025-08-17 · How we verify

NCT07121868: BEVocCapATCO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bioequivalence Assessment Between Two Cariprazine Hard Capsule Formulations

Completed Phase 1 Last updated 17 August 2025

What this trial tests

Phase 1 trial testing Test Product (Vocarzine) in Bioequivalence Study in Healthy Subjects in 29 participants. Completed in 23 January 2025.

Timeline

3 August 2024

Primary endpoint
23 January 2025

23 January 2025

Quick facts

Lead sponsor	Aya Mohammed Abdel Magid Abdel Hamid
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	29
Start date	3 August 2024
Primary completion	23 January 2025
Estimated completion	23 January 2025
Sites	1 location across Egypt

Drugs / interventions tested

Test Product (Vocarzine) — full drug profile →
Reference (R) Reagila ® — full drug profile →

Conditions studied

Bioequivalence Study in Healthy Subjects — all drugs for Bioequivalence Study in Healthy Subjects →

Sponsor

Aya Mohammed Abdel Magid Abdel Hamid — full company profile →

Who can join

Adults 18 to 55, any sex, with Bioequivalence Study in Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An open label, randomized, single-dose, two sequence, two-period, crossover study to assess the bioequivalence of Cariprazine in Vocarzine 1.5 mg hard gelatin capsule (Test product) in comparison with Reagila® 1.5 mg hard capsules (Reference product) in 30 healthy subjects under fasting conditions

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Bioequivalence evaluation of two cariprazine hard capsule formulations.
Rezk MR, Badr KA, Hosny AAEH, Abdel Magid AM. · · 2026 · PMID 41689599 · DOI 10.1007/s00210-026-05017-1

Verify or expand the search:

Other Aya Mohammed Abdel Magid Abdel Hamid trials

Trials by the same sponsor.

NCT07127094 — Bioequivalence Assessment Between Two Imeglimin Hydrochloride Film Coated Tablet Formulations · Phase 1 · completed
NCT06969963 — Bioequivalence Assessment Between Two Perampanel Oral Suspension Formulations · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07121868 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aya Mohammed Abdel Magid Abdel Hamid
Last refreshed: 17 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07121868.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing